
Polyphor AG bags funding for murepavadin
Swiss Polyphor AG (Allschwil) is developing its lead Outer Membrane Protein Targeting Antibiotic (OMPTA) candidate inhaled murepavadin against...

Biomarker identifies high-risk COVID-19 patients
The findings of virologists headed by Elisabeth Puchhammer-Stöckl from the Medical University Vienna may pave the way to early identification of...

Centogene and Anylam launch clinical programme
ATTRv is an autosomal dominant condition caused by a pathogenic variant in the TTR gene coding for transthyretin (prealbumin)....

V-Bio Ventures launches second fund at €78m
With the investment, the Belgian biotech sector gets a cash injection. According to V-Bio Ventures, the new fund will build on the investment...

Cellectis and Cytovia in US$760m licence deal
Cytovia Therapeutics, Inc. and French Cellectis SAS have struck a licence deal to combine their different expertises in allogenic cancer cell...

European Circular Bioeconomy Fund growing
Nurition world market leader Nestlé as well as Neste Oyj, Volkswohl Bund Versicherungen, NRW.BANK and an undisclosed family office contributed to the...

MosaMeat BV closes US$85m Series B financing
While EU policymakers are yet discussing the green deal or farm to fork strategies, Dutch MosaMeat BV is launching a new era of biotechnologically...